New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
06:55 EDTTPI, TPI, TPI, ANX, ANX, ANX, AGEN, AGEN, AGEN, CTSO, CTSO, CTSO, ATOS, ATOS, ATOS, SYN, SYN, SYN, OXBT, OXBT, OXBT, CLRX, CLRX, CLRX, BONE, BONE, BONEOneMedPlace to host a forum
6th Annual OneMedForum 2013 is being held in San Francisco on January 7-9.
News For TPI;ANX;AGEN;CTSO;ATOS;SYN;OXBT;CLRX;BONE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:10 EDTAGENMaidStone Life Sciences to hold a conference
Subscribe for More Information
March 24, 2015
08:12 EDTATOSAtossa Genetics launches FullCYTE Breast Aspirator in U.S.
Subscribe for More Information
March 22, 2015
11:13 EDTSYNSynthetic Biologics has lunch meeting with Philadelphia Securities Association
Subscribe for More Information
March 19, 2015
09:20 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
06:58 EDTSYNSynthetic Biologics announces positive PK results from SYN-004 trials
Subscribe for More Information
March 17, 2015
16:39 EDTBONEBacterin sees FY15 revenue $40M-$42M, consensus $35.18M
Subscribe for More Information
16:37 EDTBONEBacterin reports Q4 EPS (49c), one estimate (35c)
Subscribe for More Information
March 16, 2015
14:03 EDTSYNSynthetic Biologics downgraded to Hold from Buy at Maxim
Maxim downgraded Synthetic Biologics to Hold following management's decision no to move SYN-005 for pertussis until funding is found, which creates another uncertainty regarding the timeline. Price target is $3.
07:33 EDTBONEBacterin announces contract extension with Novation
Bacterin International Holdings announced that it has extended its contract with Novation for an additional year. The extension will allow Bacterin to continue to supply Novation members with OsteoSponge, OsteoSelect DBM Putty, and other proprietary Bacterin allografts. Novation develops and manages competitive contracts with more than 700 suppliers. As a biologic supplier, Bacterin is one of only three companies with a contract for demineralized bone matrix technologies and one of four allograft suppliers. This gives Bacterin a competitive advantage in comparison to many biologic providers that do not have an agreement with Novation. Since entering into a contract in 2012, Bacterin has worked closely with Novation in several areas including helping to drive contract utilization with its members, adding value for the facility and their patients, and helping its members recognize savings without compromising safety or quality. In 2014, approximately 25% of Bacterin's revenues were generated by Novation members.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use